Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Research in Real-Life Ltd
With
Chiesi Farmaceutici S.p.A.
To evaluate whether beclomethasone dipropionate / formoterol (BDP/FOR; Fostair® 100/6) is at least equivalent in terms of exacerbation prevention to fluticasone dipropionate / salmeterol (FP/SAL; Seretide®) in matched asthma patients switching to BDP/FOR following treatment with FP/SAL in normal clinical practice compared with patients not switched. To evaluate respiratory outcomes for Fostair in comparison to Seretide using a UK primary care database (in patients switched for cost rather than clinical reasons).
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged: 18-80 years 61-80 years to be non-smokers only
Evidence of asthma: a diagnostic code for asthma or two scripts for asthma..
Baseline FP/SAL therapy: ≥2 prescription for ICS/LABA therapy as FP/SAL
Evidence of Continuing Therapy: Include only patients who receive ≥2 prescriptions for the therapy under study during the outcome year (i.e. ≥1 prescription at the index date and ≥1 other). UK average is 3-4 prescriptions refilled per year, so ≥2 ensures capture of "real-life" data.
Evidence of Switching for economic reasons: FP/SAL patients from practices with ≥5 switches to Fostair in a 3 month period to minimise data taken from switching of anomalous patients; optimal practices for inclusion are those switching "wholesale" for economic reasons.
You may not be if
Any chronic respiratory disease other than asthma
Are receiving maintenance oral steroid therapy during baseline period
Clareo Health | Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management
